Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity
Authors' conclusion
Three months of supplementation with myo-inositol and zinc were beneficial on lipid profile and in managing obesity complications at least in subjects with severe phenotype. Thus, myo-inositol and zinc could be used as non-pharmacological agents. This work suggests a long-term study with a larger sample size to enrich the findings.
Study context
- Population
- Patients aged 10–18 years, Tanner stage ≥3, with obesity and insulin resistance, North Italy; all on isocaloric Mediterranean-style diet50 completed
- Participants
- 56 patients
- Comparison
- Myo-inositol + zinc gluconate + galactooligosaccharides (GOS) vs placebo with GOS only
- Primary endpoint
- Insulin resistance index (HOMA-IR)
- Follow-up
- 3 months
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
HOMA-IR
- TRT did not improve insulin resistance compared to placebo (PLC)
Further findings
| Outcome | P value |
|---|---|
| HDL cholesterol · 3 monthsImproved with TRT | P = 0.05 |
| Fasting insulin, stratified post hoc analysis by obesity gradeLower with TRT; greater effect in severe obesity · post hoc analysis | P = 0.0137 |
| HOMA-IR, stratified post hoc analysis by obesity gradeLower with TRT; greater effect in severe obesity · post hoc analysis | P = 0.0273 |
Safety
- No adverse events were detected
Original publication
Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity. Diabetes Obes Metab. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →